Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

NCT06278870 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

312

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Metastatic Breast Cancer
First-line Treatment

Interventions

DRUG: disitamab vedotin
DRUG: Pyrotinib
DRUG: trastuzumab
DRUG: Pertuzumab
DRUG: taxane drug

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University